Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

NCT05001945 ↗

Phase 2 Completed 200 enrolled Mineralys Therapeutics Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

Timeline

Start: 2021-07-01
Primary completion: 2022-09-07
Completion: 2022-10-07

Publications

Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, Slingsby BT, Nissen SE; Target-HTN Investigators. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023 Sep 26;330(12):1140-1150. doi: 10.1001/jama.2023.16029.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	lorundrostat	Small molecule	12.5 mg	Oral
Subject	lorundrostat	Small molecule	25 mg	Oral
Subject	lorundrostat	Small molecule	50 mg	Oral
Subject	lorundrostat	Small molecule	100 mg	Oral

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Summary

Timeline

Publications

Drugs

Indications